PL3064579T3 - Kompozycje farmaceutyczne i zastosowania medyczne uzyskanych metodami inżynierii ludzkich arginaz - Google Patents
Kompozycje farmaceutyczne i zastosowania medyczne uzyskanych metodami inżynierii ludzkich arginazInfo
- Publication number
- PL3064579T3 PL3064579T3 PL16163214T PL16163214T PL3064579T3 PL 3064579 T3 PL3064579 T3 PL 3064579T3 PL 16163214 T PL16163214 T PL 16163214T PL 16163214 T PL16163214 T PL 16163214T PL 3064579 T3 PL3064579 T3 PL 3064579T3
- Authority
- PL
- Poland
- Prior art keywords
- pharmaceutical compositions
- medical uses
- engineered human
- human arginases
- arginases
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/50—Hydrolases (3) acting on carbon-nitrogen bonds, other than peptide bonds (3.5), e.g. asparaginase
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/78—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y305/00—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5)
- C12Y305/03—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5) in linear amidines (3.5.3)
- C12Y305/03001—Arginase (3.5.3.1)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Inorganic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Enzymes And Modification Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US11021808P | 2008-10-31 | 2008-10-31 | |
| EP16163214.6A EP3064579B1 (en) | 2008-10-31 | 2009-11-02 | Pharmaceutical compositions and medical uses of engineered human arginases |
| EP09824219.1A EP2350273B1 (en) | 2008-10-31 | 2009-11-02 | Compositions of engineered human arginases and methods for treating cancer |
| PCT/US2009/062969 WO2010051533A2 (en) | 2008-10-31 | 2009-11-02 | Compositions of engineered human arginases and methods for treating cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3064579T3 true PL3064579T3 (pl) | 2021-07-05 |
Family
ID=42129584
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL16163214T PL3064579T3 (pl) | 2008-10-31 | 2009-11-02 | Kompozycje farmaceutyczne i zastosowania medyczne uzyskanych metodami inżynierii ludzkich arginaz |
| PL20171935.8T PL3778885T3 (pl) | 2008-10-31 | 2009-11-02 | Kompozycje modyfikowanych ludzkich arginaz i sposoby leczenia raka |
| PL09824219.1T PL2350273T3 (pl) | 2008-10-31 | 2009-11-02 | Kompozycje modyfikowanych ludzkich arginaz i sposoby leczenia nowotworu złośliwego |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL20171935.8T PL3778885T3 (pl) | 2008-10-31 | 2009-11-02 | Kompozycje modyfikowanych ludzkich arginaz i sposoby leczenia raka |
| PL09824219.1T PL2350273T3 (pl) | 2008-10-31 | 2009-11-02 | Kompozycje modyfikowanych ludzkich arginaz i sposoby leczenia nowotworu złośliwego |
Country Status (15)
| Country | Link |
|---|---|
| US (8) | US8440184B2 (pl) |
| EP (5) | EP3957728A1 (pl) |
| JP (2) | JP5695570B2 (pl) |
| CA (1) | CA2742497C (pl) |
| DK (3) | DK3778885T3 (pl) |
| ES (3) | ES2945580T3 (pl) |
| FI (1) | FI3778885T3 (pl) |
| HK (1) | HK1160165A1 (pl) |
| HR (1) | HRP20230484T1 (pl) |
| HU (1) | HUE062354T2 (pl) |
| LT (1) | LT3778885T (pl) |
| PL (3) | PL3064579T3 (pl) |
| PT (1) | PT3778885T (pl) |
| SI (1) | SI3778885T1 (pl) |
| WO (1) | WO2010051533A2 (pl) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL3064579T3 (pl) * | 2008-10-31 | 2021-07-05 | Aerase, Inc. | Kompozycje farmaceutyczne i zastosowania medyczne uzyskanych metodami inżynierii ludzkich arginaz |
| CA2766039A1 (en) * | 2009-06-29 | 2011-01-20 | The Board Of Regents Of The University Of Texas System | Arginase formulations and methods |
| WO2012061015A2 (en) * | 2010-11-03 | 2012-05-10 | Scott & White Healthcare | L-citrulline supplementation during arginine depletion therapy with arginase |
| CN102234624B (zh) * | 2011-04-25 | 2013-03-06 | 武汉远大弘元股份有限公司 | 一种表达产生枯草芽孢杆菌精氨酸酶的基因工程菌及构建方法 |
| CN103184208B (zh) * | 2011-12-27 | 2015-09-16 | 拜奥生物科技（上海）有限公司 | 人精氨酸酶和定点聚乙二醇化人精氨酸酶及其应用 |
| US9011845B2 (en) | 2012-06-26 | 2015-04-21 | Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Methods for treatment of inflammatory and infectious viral diseases |
| WO2014003850A2 (en) * | 2012-06-26 | 2014-01-03 | Timothy Paul Foster | Methods for treatment of ocular diseases |
| US10478498B2 (en) | 2014-06-20 | 2019-11-19 | Reform Biologics, Llc | Excipient compounds for biopolymer formulations |
| US11357857B2 (en) | 2014-06-20 | 2022-06-14 | Comera Life Sciences, Inc. | Excipient compounds for protein processing |
| US20160074515A1 (en) | 2014-06-20 | 2016-03-17 | Reform Biologics, Llc | Viscosity-reducing excipient compounds for protein formulations |
| TWI790481B (zh) | 2014-07-08 | 2023-01-21 | 開曼群島商瑞華藥業集團 | 精胺琥珀酸合成酶之抗體及相關方法 |
| HRP20220406T1 (hr) | 2016-08-08 | 2022-05-27 | Aerase, Inc. | Pripravci i metode za liječenje raka deplecijom arginina i imunoonkološkim sredstvima |
| JP7211938B2 (ja) | 2016-10-07 | 2023-01-24 | アイオー バイオテック エーピーエス | 免疫原性アルギナーゼペプチド |
| WO2018167778A1 (en) | 2017-03-12 | 2018-09-20 | Yeda Research And Development Co. Ltd. | Methods of diagnosing and prognosing cancer |
| WO2018167780A1 (en) | 2017-03-12 | 2018-09-20 | Yeda Research And Development Co. Ltd. | Methods of prognosing and treating cancer |
| TW201910513A (zh) * | 2017-08-16 | 2019-03-16 | 香港商鎧耀波麗堂（香港）有限公司 | 胺基酸耗竭治療的組合物及方法 |
| CA3084801A1 (en) * | 2017-12-05 | 2019-06-13 | Aerase, Inc. | Method and composition for treating arginase 1 deficiency |
| MX2021004463A (es) | 2018-10-19 | 2021-08-24 | Aerase Inc | Terapia de disminución de arginina para el tratamiento de la deficiencia de gamt. |
| BR112022003633A2 (pt) * | 2019-08-30 | 2022-06-07 | Aeglea Biotherapeutics Inc | Métodos para produção de arginase 1 recombinante humana e usos da mesma |
| WO2022195629A1 (en) * | 2021-03-18 | 2022-09-22 | National Institute Of Pharmaceutical Education And Research (Niper) | Engineered arginase constructs, method of generation and uses thereof |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH02117383A (ja) * | 1988-10-26 | 1990-05-01 | Tosoh Corp | ヒトアルギナーゼの製造方法 |
| US5780286A (en) * | 1996-03-14 | 1998-07-14 | Smithkline Beecham Corporation | Arginase II |
| WO2003063780A2 (en) * | 2002-01-25 | 2003-08-07 | Cancer Treatments International | Therapeutic composition for treatment of cancer by arginine depletion |
| HK1053577A2 (en) | 2002-06-20 | 2003-10-10 | Bio Cancer Treatment Int Ltd | Pharmaceutical composition and method of treatment of human malignanices with arginine deprivation |
| CN1745847A (zh) * | 2004-09-08 | 2006-03-15 | 康达医药科技有限公司 | 用精氨酸酶治疗肝炎的药物组合物和方法 |
| PL3064579T3 (pl) * | 2008-10-31 | 2021-07-05 | Aerase, Inc. | Kompozycje farmaceutyczne i zastosowania medyczne uzyskanych metodami inżynierii ludzkich arginaz |
-
2009
- 2009-11-02 PL PL16163214T patent/PL3064579T3/pl unknown
- 2009-11-02 SI SI200932181T patent/SI3778885T1/sl unknown
- 2009-11-02 CA CA2742497A patent/CA2742497C/en active Active
- 2009-11-02 PT PT201719358T patent/PT3778885T/pt unknown
- 2009-11-02 ES ES20171935T patent/ES2945580T3/es active Active
- 2009-11-02 ES ES09824219.1T patent/ES2574139T3/es active Active
- 2009-11-02 EP EP21182887.6A patent/EP3957728A1/en active Pending
- 2009-11-02 US US12/610,685 patent/US8440184B2/en not_active Ceased
- 2009-11-02 LT LTEP20171935.8T patent/LT3778885T/lt unknown
- 2009-11-02 DK DK20171935.8T patent/DK3778885T3/da active
- 2009-11-02 HU HUE20171935A patent/HUE062354T2/hu unknown
- 2009-11-02 EP EP09824219.1A patent/EP2350273B1/en active Active
- 2009-11-02 EP EP21182873.6A patent/EP3957727A1/en active Pending
- 2009-11-02 EP EP16163214.6A patent/EP3064579B1/en active Active
- 2009-11-02 WO PCT/US2009/062969 patent/WO2010051533A2/en active Application Filing
- 2009-11-02 PL PL20171935.8T patent/PL3778885T3/pl unknown
- 2009-11-02 ES ES16163214T patent/ES2838848T3/es active Active
- 2009-11-02 JP JP2011534855A patent/JP5695570B2/ja active Active
- 2009-11-02 DK DK09824219.1T patent/DK2350273T3/en active
- 2009-11-02 DK DK16163214.6T patent/DK3064579T3/da active
- 2009-11-02 EP EP20171935.8A patent/EP3778885B1/en active Active
- 2009-11-02 FI FIEP20171935.8T patent/FI3778885T3/fi active
- 2009-11-02 HR HRP20230484TT patent/HRP20230484T1/hr unknown
- 2009-11-02 PL PL09824219.1T patent/PL2350273T3/pl unknown
-
2012
- 2012-01-13 HK HK12100429.7A patent/HK1160165A1/zh unknown
-
2013
- 2013-04-16 US US13/863,448 patent/US9050340B2/en active Active
- 2013-11-22 JP JP2013241687A patent/JP2014036676A/ja not_active Withdrawn
-
2014
- 2014-05-12 US US14/275,259 patent/US20140242060A1/en not_active Abandoned
-
2015
- 2015-05-14 US US14/711,916 patent/USRE46423E1/en active Active
-
2016
- 2016-09-20 US US15/270,955 patent/US10098933B2/en active Active
-
2018
- 2018-07-16 US US16/035,877 patent/US20190000939A1/en not_active Abandoned
-
2020
- 2020-11-12 US US17/096,379 patent/US20210128703A1/en not_active Abandoned
-
2023
- 2023-01-26 US US18/160,112 patent/US20240009283A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PL3064579T3 (pl) | Kompozycje farmaceutyczne i zastosowania medyczne uzyskanych metodami inżynierii ludzkich arginaz | |
| IL276157A (en) | Pharmaceutical preparations and methods for transferring them related to them | |
| EP2262469A4 (en) | SKIN CARE COMPOSITIONS AND METHODS OF USE | |
| EP2498988A4 (en) | MEDICAL ARTICLES AND METHODS OF MANUFACTURING USING MISCIBLE COMPOSITION | |
| PT2322221E (pt) | Composição farmacêutica para tratamento e prevenção de cancro | |
| EP2528603A4 (en) | PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF PAIN AND OTHER INDICATIONS | |
| IL206080A0 (en) | Pharmaceutical composition for use in the treatment and/or the prevention of osteoarticular diseases | |
| EP2450046A4 (en) | MEDICALLY ACTIVE COMPOSITION FOR THE TREATMENT OF BRONCHITIS AND PREPARATION THEREOF | |
| IL210810A0 (en) | Compositions for the treatment of pain and/or inflamtion | |
| EP2432492A4 (en) | APPLICATION AND USE OF PRG4 AND THERAPEUTIC MODULATION THEREOF | |
| IL207546A0 (en) | Pharmaceutical composition for use in the treatment or prevention of osteoarticular diseases | |
| EP2170404A4 (en) | COMPOSITIONS WITH HUMAN EGFR SIRNA AND METHOD OF USE | |
| GB201302653D0 (en) | Pharmaceutical compositions and methods of treatment | |
| EP2651439A4 (en) | COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING HUMAN ADENOVIRUS 36 INFECTION | |
| GB201008885D0 (en) | Methods for administration and formulations for the treatment of reginal adipose tissue | |
| ZA201104882B (en) | Pharmaceutical compositions with superior product performance and patient compliance | |
| PL2474306T3 (pl) | Kompozycja w postaci cząstek stałych i zawierająca ją kompozycja lecznicza | |
| EP2305300A4 (en) | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT AND PREVENTION OF CANCER | |
| IL219018A (en) | Radzolid Pharmaceuticals and Uses | |
| IL216529A0 (en) | Pharmaceutical compositions comprising extracts of s arcopoterium spinosum, components thereof, and uses thereof | |
| AU2007900995A0 (en) | Therapeutic Compositions and Methods of Treatment |